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Abstract
Background: Estimation of Influenza vaccine effectiveness (VE) varies with study design, clinical outcome considered and
statistical methodology used. By estimating VE using differing outcomes and statistical methods on the same cohort of
individuals the variability in the estimates produced can be better understood. The Pandemic Influenza Primary Care
Reporting (PIPeR) cohort of approximately 193,000 individuals was used to estimate pandemic VE in Scotland during season
2009–10. VE results for three outcomes; influenza related consultations, virological confirmed influenza and death were
considered. Use of individualised records allowed all models to be adjusted for age, sex, deprivation, risk status relating to
chronic illnesses, seasonal vaccination status and a marker of the individual’s propensity to consult. For the consultation and
death outcomes, VE was calculated by comparing consultation rates in the unvaccinated and vaccinated groups, adjusted
for the listed factors, using both Cox and Poisson regression models. For the consultation outcome, the unvaccinated group
was split into individuals before vaccination and those never vaccinated to allow for potential differences in the health
seeking behaviour of these groups. For the virology outcome estimates were calculated using a generalised additive logistic
regression model. All models were adjusted for time. Vaccine effect was demonstrated for the influenza-like illness
consultation outcome using the Cox model (VE = 49% 95% CI (19%, 67%)) with lower estimates from the model splitting the
before and never vaccinated groups (VE = 34.2% with 95% CI (20.5%, 58.9%)). Vaccine effect was also illustrated for overall
mortality (VE = 40% (95% CI 18%, 56%)) and a virological confirmed subset of symptomatic individuals (VE = 60% (95% CI
238%, 89%)).
Conclusions: This study illustrates positive point estimates of Influenza VE across methodology and outcome for a single
cohort of individuals during season 2009–10. Understanding of potential differences between approaches aids
interpretation of VE results in future seasons.
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Introduction
Influenza vaccine effectiveness (VE) requires yearly assessment
due to the evolution of the virus and subsequent reformulation of
the vaccination. Such changes influence the estimates of VE
between seasons. Within a season, differences in estimates for the
same vaccination may vary between studies due to methodological
differences in the study design, the statistical method employed
and the outcome measure used. Generally VE studies fall into one
of three designs; case-control (including test negative), cohort or
screening. The design of the study dictates the method of analysis
used. In the current European context, only observational studies
could be used to provide real time influenza VE estimates [1]. In
the case of observational cohort studies, the methodology used
may be logistic regression, Poisson regression or Cox proportional
hazards. For the same outcome these may produce differing
estimates.
Estimates may also differ dependent on the clinical outcomes
used to measure influenza VE. Typical outcomes are influenza-
related GP consultation rates, laboratory confirmed diagnosis,
hospitalisation rates and death rates (all or influenza-specific
causes). Valenciano et al. [2] highlight that the various clinical
outcomes used have differing sensitivity and specificity, with low
specificity in particular, leading to underestimation of influenza
VE estimation.
There have been a number of recent publications on the
vaccine effect of the pandemic H1N1v vaccine delivered in the
autumn of 2009. All have been on virological confirmed cases of
influenza either from GP sentinel schemes using a defined
protocol for the swabbing of patients with symptoms or from
hospital cases. In England and Scotland a test negative design
estimated that the pandemic vaccine had a vaccine effect of 72%
(95% confidence interval (CI): 21% to 90%) [3]. A multicentre
case control study in seven countries in Europe provided
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estimates of 71.9% (95% CI 45.6–85.5) [2]. Both of these studies
had issues with missing data, particularly the UK study where
vaccine status was unknown for many patients; imputation was
used in the multicentre study primarily for missing co morbidity
information. A Canadian study reported that the vaccine effect
was 93% (95% CI 69% to 98%) [4]. In a test negative case
control study of hospitalisations for influenza in Castellon, Spain
a vaccine effect of 90% (95% CI, 48–100%) was reported [5].
Estimates of VE of 96.8%; (95% CI 95.2–97.9%) in persons aged
14–59 years and 83.3% (95% CI:71.0–90.5%) in those 60 years
or older were provided using the screening method on virological
samples in Germany [6].
Estimates of seasonal influenza VE in Scotland, using
influenza-related consultations within a cohort of patients
registered at a number of general practices have been estimated
at Health Protection Scotland (HPS) since 2008. For season
2009–2010, we present estimates of pandemic influenza VE
calculated using differing statistical methodologies. In addition we
present the effect of varying the outcome measure used, firstly in
terms of the consultation definition and then considering
laboratory confirmed diagnosis and death as end-points. In this
way, we aim to understand the variation in VE estimates for the
same cohort and identify robust methods for estimating pandemic
influenza VE from routinely collected consultation data. Such
data has the facility to provide timely estimates throughout the flu
season.
Methods
Study design
The Pandemic Influenza Primary care Reporting (PIPeR)
cohort is based upon 37 practices which were drawn from a
sentinel surveillance network of GP practices contributing to the
Practice Team Information (PTI) network [7]. In season 2009–
2010, PIPeR covered approximately 206,000 patients, around 4%
of the Scottish population. Thirty-two of these practices, covering
approximately 193,000 patients, gave permission for the extract of
pandemic vaccination data alongside the routinely collected data.
Seasonal vaccination data are routinely collected but as the
pandemic vaccination was new, separate consent for the data
extraction had to be undertaken.
The PIPeR cohort contains anonymous individualised records
for participants who have at least one year of recorded database
history prior to the start of the study, detailing the age, sex,
deprivation index, based upon postcode sector and linked to the
Carstair’s measure [8], and at-risk status for influenza. Daily
automated updates provide information on vaccination status
(seasonal influenza and pneumococcal polysaccharide vaccination)
and consultations corresponding to acute respiratory infections
(ARI) and influenza-like illness (ILI). Date of death was recorded
and those who died prior to the start date of the study were
removed from consideration.
Individuals ‘at risk’ of complications following influenza
infection were recorded. The conditions covered were: diabetes,
coronary heart disease, chronic liver disease, chronic respiratory
disease, chronic liver disease, neurological disorders and immu-
nosuppression. Risk group status was poorly recorded for those
over 65 years of age, as they are routinely targeted for
vaccination. Risk group status was assigned at the beginning of
the cohort and individuals were assumed to remain in that status
throughout the period of analysis. The Community Health Index
(CHI) is also available at HPS in password protected databases
and this is a unique number which can be used to link to other
health systems.
Outcomes
The endpoints considered were consultation rates, laboratory
confirmed infection and death.
Three classifications of consultation were considered: influenza-
like illness consultations denoted ILI, acute respiratory infection
consultations including influenza-like illness denoted ARI, and a
combined total number of both consultations, excluding those
which are Asthma-related, denoted ILIARI. For each endpoint,
the consultation was excluded from the analysis if it occurred
within 7 days of the pandemic influenza vaccination to allow for
the time required for a protective effect to be established. For
seasonal influenza vaccination the conventional exclusion period is
14 days, however studies at the Health Protection Agency and the
sensitivity analysis in Hardelid et al. [3] suggest 7 days is sufficient
for the Influenza A (H1N1v) vaccination.
Among patients who attended the PIPeR practices, a subset of
those with clinical symptoms which resembled those associated
with influenza like illness, were swabbed as part of the Scottish
Sentinel swabbing scheme.
The date of death was extracted from the practice database but
there is no information on cause of death. The analysis is based
upon dates of death extracted from the practice records up to 30th
June 2010. In a sensitivity analysis to investigate delays in
recording date of death, the extract was carried on to the end of
October 2010 and an additional 2 deaths within the study period
were noted.
Vaccination status and study period
Influenza vaccination was coded as a dichotomous time-
dependent variable with recording of both the seasonal and
pandemic vaccination in season 2009/2010. The study period is
from October 1st 2009, (26th October, 2009 was the date of the
first pandemic Influenza A (H1N1v) vaccinations in the UK) and
ended on 31st March 2010. Seasonal vaccinations from September
1st, 2009 were recorded.
Statistical analysis. The analysis differed depending upon
the outcome and statistical method used. For consultation
outcomes there were potentially multiple events per patient
whereas for death and virological status each patient had only
one possible event.
There are two time dependent covariates – Seasonal vaccine
status and pandemic influenza A (H1N1v) vaccine status and
changes to either result in a split of the patients follow up record.
Such time dependency makes Cox proportional hazards [9] an
appropriate method to use.
The effect of the following covariates which may influence
vaccine effectiveness were considered for all outcomes: age group,
gender, risk group status (in at least one clinical risk group, yes/
no), number of ILIARI consultations in the previous influenza
season (0, 1, 2+), seasonal influenza vaccination status in the
previous season, seasonal influenza vaccination status in the
current season and deprivation represented using quintiles based
on the Carstair’s index [8]. Estimates of adjusted vaccine
effectiveness, using Cox regression were calculated as VE= (1-
RR)*100 where the relative risk (RR) is the exponent of the hazard
ratio of vaccine status (vaccinated/not vaccinated).
Consultation outcome
Each new consultation event leads to a new record in the set up
for the time dependent cox model. Multiple consultations for the
same event on the same day were counted as one consultation
however two consultations one day apart were counted as two
consultations. An extension to the standard time dependent Cox
Variation in Influenza Vaccine Effectiveness
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model, using robust standard errors, to account for clustering of
individuals within practices, is also considered.
The Cox model can be recast as a Poisson linear-regression
model [10] by aggregating the person time at risk. Time was
stratified in weeks and the number of consultation events in each
covariate pattern and vaccine status per week was calculated along
with the time at risk in that week. In the Poisson model, adjusted
vaccine effectiveness is calculated as VE= (1-RR)*100 where RR
is the ratio of the consultation rate among those unvaccinated
compared to those vaccinated.
The Cox and Poisson models make no distinction between the
consultation rates in those never vaccinated relative to the rates in
those who are ultimately vaccinated but are prior to vaccination.
In an extension of the Poisson model, a patient’s exposure to
vaccine at any time was recoded as never vaccinated, before
vaccination and after vaccination. A comparison of the consulta-
tion rates before and after vaccination eliminates some of the
effects of confounding variables and the propensity to consult, and
provided the temporal trend is modelled appropriately will give an
estimate of vaccine effect. In the extended Poisson model, adjusted
vaccine effectiveness was calculated as VE= (1-RR)*100 where
RR is the ratio of the consultation rate after vaccination compared
to the consultation rate before vaccination.
Both models using the Poisson regression framework were
adjusted for time by using a factor to differentiate weeks since the
start date and so accounting for changes in the background rate of
disease in the community.
Finally, the screening method [11] was used to illustrate
estimates of VE in a situation where only aggregate data was
available. To do so the data was aggregated for each GP practice
to give summaries of; the number of consultations in vaccinated
individuals, the total number of consultations and the vaccination
coverage in that practice. VE is calculated using a generalised
linear mixed model where the log odds of a consultation in the
vaccinated group is the response, the log odds of the vaccine
coverage is the offset and the GP practice is the random effect.
Death outcome
The death rates among those vaccinated and unvaccinated were
compared through a time dependent cox model and a Poisson
regression model based upon calculation of the person time at risk
for each week throughout the observation period. Adjustment was
made for the confounding factors.
Virology outcome
HPS has data on the results of all virological swab tests for
H1N1v influenza during the pandemic season 2009–10. The
sample are from all hospital laboratories in Scotland, collected
through the Electronic Communication of Surveillance in Scot-
land (ECOSS) system [12], and the West of Scotland Regional
Virus Lab which tests the majority of samples from general
practice, including those in the sentinel surveillance scheme. All
patients who were tested had acute respiratory symptoms and were
tested for clinical reasons. There were 13623 individuals with at
least one virological test. Many individuals had multiple tests. The
first positive test was selected for those with a positive result and
the first test was selected for those with all negative results.
Virological data were linked to the cohort on the basis of the
community health index number (CHI Number). Laboratory
samples without a valid CHI Number were excluded as they could
not be linked 211.6% of records
A nested case control analysis was used to estimate vaccine
effectiveness by fitting a generalised additive logistic regression
model with those who tested negative serving as the controls [13].
As the vaccination was administered to individuals at differing
times through the swabbing interval the comparison of the rates of
swab positivity among those vaccinated or unvaccinated at the
time of swabbing was adjusted for the temporal trends in swab
positivity which was modelled by a quadratic trend based upon
week of sample collection.
All statistical analysis was conducted using R version 2.12.2.
Results
Demographics, vaccine uptake and consultations
The pandemic influenza cohort is composed of 193,034 eligible
individuals, 49.8% male, with mean age 40.3 years. Most
individuals are in the 15–44 year old age group (41.1%), with
16.0% over 65 and 4.7% under 5 years old (Table 1). Of those
under 65, 14.8% are in at least one clinical risk group. The most
commonly recorded risk group in those under 65 is chronic
respiratory disease (5.4%) followed by chronic heart disease (3.7%)
and diabetes (3.2%).
Pandemic and seasonal vaccination uptake by age is summa-
rised in Table 2. For those under 45 in a clinical risk group,
H1N1v vaccine uptake is higher than seasonal uptake in the
youngest age groups, 0–4 years and 5–14 years. H1N1v uptake is
highest in those aged 0–4 years (58.5%) followed by those aged 5–
14 years (56.5%). As age increases the differential between
seasonal and pandemic vaccination becomes less with similar
uptake in the 15–44 year old age group. In the 45–64 year old age
group, uptake for the seasonal vaccination exceeds the pandemic
uptake. Uptake for those in a clinical risk group is lowest in those
aged 15–44 years (39.7%). Overall, H1N1 vaccine uptake is lowest
in those aged over 65 (34.8%).
Figure 1 shows the pandemic and seasonal vaccine uptake over
time for ‘‘at risk’’ individuals. Figure 1A illustrates the commence-
ment of the pandemic influenza vaccination in late October 2009
with the majority of the vaccinations administered through
November and December 2009. This is in contrast to the seasonal
influenza vaccine uptake where the uptake in the elderly had been
largely completed by the end of October (Figure 1B). In contrast, a
substantial proportion of those in clinical at risk groups only received
their seasonal influenza vaccination in the period after1st November.
Figure 2 demonstrates the increased clinical reporting of cases of
influenza like illness and other acute respiratory infections
reported in the 37 PIPeR GP practices from early July 2009
when routine swabbing of a subset of patients attending with
influenza-like illness symptoms began, until the 31 January 2010.
Reporting increased in August building to a peak in late October
and November before reducing across December and January.
The same figure shows that swab positivity for pandemic influenza
lags behind the clinical peak by between one to two weeks due to
the time delay in testing and reporting. Figure 1A demonstrates
that much of the pandemic influenza vaccine administered in the
cohort was either at or shortly after the peak in clinical illness
presentation.
The number of consultations and consultation rates for the
three categories ILI, ILIARI and ARI are summarised in Tables 3
and 4 for both vaccine classification rules used in the statistical
models. As all consultations are nested within the ARI category,
this has the largest number of consultations followed by ILIARI
and then ILI categories. Examining the crude consultation rates
for ILI in Table 3, the rate in the unvaccinated group is
approximately 4 times that of those vaccinated (0.454 consulta-
tions per 1000 person-week (pw) compared to 0.111 consultations
per 1000 pw). Splitting the unvaccinated group into those never
vaccinated and those individuals who are in the time period before
Variation in Influenza Vaccine Effectiveness
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vaccination (Table 4), the consultation rates in those prior to
vaccination are slightly higher than those never vaccinated,
indicating a possible difference in their consultation behaviour
for ILI. Considering the less-specific consultation codes, the
difference between the before vaccination and the never
vaccinated groups becomes more distinct. Considering ILIARI,
when comparing the unvaccinated and vaccinated groups, the
consultation rate in the vaccinated group is higher than the
unvaccinated group (3.872 per 1000 pw compared to 2.899 per
1000 pw) crudely indicating a negative VE. When looking at the
Table 1. Demographics of the PIPeR cohort pandemic influenza subset.
Number Percentage
Variable Level Cohort
Has at least 1 ILIARI
consultation
Has an influenza
virology test Cohort
Has at least 1 ILIARI
consultation
Has an influenza
virology test
Gender Female 96954 4922 990 50.2 57.2 57.9
Male 96080 3690 721 49.8 42.8 42.1
Age Group ,1 235 64 10 0.1 0.7 0.6
1–4 8779 1807 252 4.5 21.0 14.7
5–9 20803 1282 288 10.8 14.9 16.8
15–44 79223 2396 714 41.0 27.8 41.7
45–64 53016 1768 335 27.5 20.5 19.6
65–74 16980 722 69 8.8 8.4 4.0
75+ 13998 573 43 7.3 6.7 2.5
Risk Group No 168189 6935 1346 87.1 80.5 78.7
Yes 24845 1677 365 12.9 19.5 21.3
Seasonal Flu Vaccine No 159242 6598 1424 82.5 76.6 83.2
Previous Season Yes 33792 2014 287 17.5 23.4 16.8
Number of ILIARI
consultations in
previous year
0 175690 5962 1300 91.0 69.2 76.0
1 13574 1633 283 7.0 19.0 16.5
2 2628 582 75 1.4 6.8 4.4
3+ 1142 435 53 0.6 5.1 3.1
Carstairs Quintile
(Deprivation)
Low - Q1 21802 1017 137 11.3 11.8 8.0
Q2 21391 1002 213 11.1 11.6 12.4
Q3 55571 2343 402 28.8 27.2 23.5
Q4 54687 2439 431 28.3 28.3 25.2
High - Q5 38649 1764 514 20.0 20.5 30.0
Unknown 934 47 14 0.5 0.5 0.8
ILIARI consultation: consultation for Influenza-like illness or acute respiratory infection excluding asthma consultations.
doi:10.1371/journal.pone.0028743.t001
Table 2. H1N1 and seasonal vaccine uptake split by clinical risk group and age group.
In Clinical Risk Group Not in Clinical Risk Group
Number
Pandemic
vaccination
uptake (%) 95% CI
Seasonal
vaccination
uptake (%) 95% CI Number
Pandemic
vaccination
uptake (%) 95% CI
Seasonal
vaccination
uptake (%) 95% CI
0–4 258 58.5 (52.4, 64.4) 27.1 (22.1, 32.9) 8756 31.7 (30.7, 32.7) 0.5 (0.3,0.6)
5–14 1516 56.5 (54.0,59.0) 37.5 (35.1, 39.9) 19287 5.1 (4.8,5.4) 0.9 (0.8, 1.0)
15–44 7728 39.7 (38.6, 40.8) 38.1 (37.1, 39.2) 71495 3.3 (3.2,3.4) 1.4 (1.3, 1.5)
45–64 14502 51.3 (50.5, 52.1) 54.6 (53.8, 55.4) 38514 3.2 (3.1, 3.4) 3.4 (3.2, 3.5)
All Under
65
24004 48 (47.4,48.6) 47.9 (47.3,48.6) 138052 5.3 (5.2, 5.4) 1.8 (1.7,1.9)
65+* 30978 34.8 (34.3, 35.3) 69.4 (68.9, 69.9) - - - - -
doi:10.1371/journal.pone.0028743.t002
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before/never vaccinated split the consultation rate in those prior
to vaccination is 6.245 per 1000 pw compared to 2.553 in the
never vaccinated group. This indicates that there may be
differences in the consultation behaviour of those individuals
who seek vaccination and those who do not. This effect is
amplified further when the least specific category, ARI is
examined. In this case those prior to vaccination have a
consultation rate of 11.781 per 1000 pw compared to 2.548 over
1000 pw in those never vaccinated. Examining the unvaccinated
and vaccinated split would again imply a negative VE whilst
comparing consultations before and after vaccination gives a
positive estimate. Such estimation based solely on consultation
rates may give misleading results as no adjustment for covariates
and the time of consultation is made.
Figure 1. Vaccination administration within the PIPeR cohort by date of administration for all individuals in a risk group. Figure 1A
shows pandemic influenza vaccination and Figure 1B seasonal influenza vaccination. All individuals over 65 are automatically ‘‘at risk’’. Those under
65 are ‘‘at risk’’ if they fall in a clinical risk group.
doi:10.1371/journal.pone.0028743.g001
Figure 2. Swab positivity and ILI/ARI GP consultation rates for the week ending 12/7/09 to 31/1/2010.
doi:10.1371/journal.pone.0028743.g002
Variation in Influenza Vaccine Effectiveness
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Vaccine effectiveness – consultation outcome
Estimates of the adjusted relative risk of a consultation in each of
the three consultation outcome categories ILIARI, ILI and ARI,
relative to the baseline group, as estimated by the before/after
Poisson regression method and Cox Proportional hazards are
summarised in Tables 5 and 6 respectively. Estimates for the
Poisson model with vaccinated compared to unvaccinated are not
presented as they are very similar to the Cox estimates. The
summarised VE estimates for all methods are presented in Table 7.
Considering the most vaccine specific outcome ILI, the covariate
and time adjusted before/after Poisson model results (Table 7)
show positive but non statistically significant VE=34.2% with
95% CI (20.05, 58.9)% for the pandemic vaccination when
comparing vaccinated individuals before and after vaccination.
Table 5 shows that receiving seasonal vaccination did not provide
any protection with vaccinated individuals shown to be 1.39 times
more likely to have an ILI after vaccination. Seasonal vaccination
in the previous season had no significant effect. Gender was found
to be significant with men 24% less likely to consult for an ILI than
women. Young children, aged 0–4 years, have the highest
likelihood of consultation and the risk of consultation decreases
linearly with age. Individuals with 2 or more ILARI consultations
in the previous season were 2.4 times more likely to consult with
an ILI. Individuals in a clinical risk group were found to be 1.6
times more likely to consult for an ILI than those not in a clinical
risk group. Little effect of deprivation was observed.
Changing the consultation outcome to ARI results in a reduced
VE=18.0% with 95% CI (11.2, 24.2)% and using outcome with
asthma codes removed, ILIARI, gives VE=27.7% (218.6, 2.3)%
(Table 7). The effect of the risk factors for each of these outcomes
is broadly similar to those described for ILI consultations apart
from individuals with 2 or more consultations in the previous
season, which for ILIARI gives RR=4.728 with 95% CI (4.438,
5.038) which is nearly double the RR observed for ILI
consultations and for deprivation.
Detailed results estimated by Cox Proportional Hazards are
shown in Table 6. VE results obtained when using Cox
Proportional Hazards with the unvaccinated/vaccinated split
and Poisson regression with the same split were broadly similar
(Table 7). Examining the Cox Proportional Hazards results in
detail, the effect of the individual risk factors across the
consultation categories is similar to the effects observed in the
before/after Poisson model. There are however some exceptions.
For the ILIARI and ARI groupings, both being in a clinical risk
group and receiving the pandemic vaccination in the previous
season have inflated RRs compared to the before/after Poisson
model (Table 5 and 6). Considering ARI in particular, the RR for
receiving seasonal influenza vaccination in the previous season
increased from 1.319 to 2.655 and for clinical risk group increased
from 1.933 to 3.113. The strength of these adjustments is reflected
in the substantial differential between the unadjusted and adjusted
models when using Cox Proportional Hazards and Poisson
Table 3. Consultation numbers and rates for those vaccinated and unvaccinated.
Consultation class Vaccination status Person-weeks (pw) No. of consultations Consultation rate per 1000 pw
ILI Unvaccinated 3161068.1 1434 0.454
Vaccinated 197823.4 22 0.111
ILIARI Unvaccinated 3161068.1 9163 2.899
Vaccinated 197823.4 766 3.872
ARI Unvaccinated 3161068.1 10789 3.413
Vaccinated 197823.4 1141 5.768
ILI: Influenza-like illness, ILIARI: Influenza-like illness and acute respiratory infections (excluding asthma), ARI: All influenza-like illness and acute respiratory infections
(including asthma).
doi:10.1371/journal.pone.0028743.t003
Table 4. Consultation numbers and rates for those never vaccinated and those vaccinated before and after vaccination.
Consultation class Vaccination status Person-weeks (pw) No. of consultations Consultation rate per 1000 pw
ILI Never vaccinated 2864993.7 1260 0.440
Before vaccination 296074.4 174 0.587
After vaccination 197823.4 22 0.111
ILIARI Never vaccinated 2864993.7 7314 2.553
Before vaccination 296074.4 1849 6.245
After vaccination 197823.4 766 3.872
ARI Never vaccinated 2864993.7 7301 2.548
Before vaccination 296074.4 3488 11.781
After vaccination 197823.4 1141 5.768
ILI: Influenza-like illness, ILIARI: Influenza-like illness and acute respiratory infections (excluding asthma), ARI: All influenza-like illness and acute respiratory infections
(including asthma).
doi:10.1371/journal.pone.0028743.t004
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regression with unvaccinated/vaccinated split methods as present-
ed in Table 7 for the ILIARI and ARI consultation groupings.
The VE estimates obtained using the screening approach, which
mirrors a situation where only aggregate end of season data is
available and therefore makes no adjustment for confounders and
temporal effects, is summarised in Table 7. The estimates from the
screening method for ILI are consistent with the time-adjusted
models. For the less specific consultation outcomes of ILIARI and
ARI the VE estimates are higher than both the time-adjusted and
the time and covariate adjusted models.
Estimates of VE for each consultation class and statistical model
used, varying by the cut-off date for analysis, are shown in
Figures 3, 4 and 5. The pattern observed between the estimates
achieved with differing methods varied with the consultation class
analysed. Results for the ILI consultation (Figure 3) class gave
comparable results for the Poisson and Cox Proportional hazards
models but results around 10 percentage points lower using the
Poisson before/after approach. The ILI response, being most
specific, was relatively invariant to the time point used as an
endpoint. For ILIARI (Figure 4) and ARI (Figure 5) consultation
categories there was variation in the estimates found dependent on
whether adjustment was performed, particularly for the Poisson
and Cox Proportional hazards models. For ARI consultations
there is more variability in the VE estimates with the cut-off date
used for analysis. The point estimates of VE decrease in February
and again in March. As ARI is less specific to influenza, this
decrease is related to the levels of influenza circulating in the
community and how these levels are relative to other respiratory
pathogens. Figure 2 illustrates that influenza levels peaked in
November, when 45% of swabs tested positive and decreased to
less than 5% positive by the end of January. Post January, only 3
further cases were virologically confirmed with the last being found
on 14th March. This indicated the lack of influenza circulating in
February and March and a higher proportion of ARI consulta-
tions in this time may be attributable to other respiratory
pathogens to which the vaccination would offer no protection.
The effect of accounting for the clustering of individuals within
practices, using robust standard errors with the Cox approach
(Table 7), widens the variability surrounding the estimates of VE
but any significant overall vaccine effect found under the original
Cox approach remains.
Vaccine effectiveness – virology outcome
Of those individuals in the cohort, a total of 1711, were
swabbed, corresponding to 8.9% of the cohort. This is a high
proportion of the swab test results (12.6% of 13623 tests) as the GP
practices in PIPeR are all in the GP sentinel surveillance scheme.
The associations between consultations for ILIARI during the
season and having a virological test are shown in Table 1. These
show that 50% of the cohort is female, 57% of those who
consulted for an ILIARI are female and the 58% of those (with
symptoms) tested are female. Thus there is no selection bias for a
virological test based upon gender. The major bias is associated
with Age where there is over representation, compared to
consultations, among those swabbed in the 15–44 age group and
under representation among children aged under 5 and adults
Table 5. Relative risk of consultation estimated by the Poisson model with before/after split for the three consultation groupings.
ILIARI ILI ARI
Variable Level RR 95% CI RR 95% CI RR 95% CI
Pandemic vaccination After 1.047 (1.077, 0.977) 0.658 (0.411, 1.052) 0.82 (0.758, 0.888)
Never 0.905 (0.931, 0.877) 1.513 (1.246, 1.839) 0.718 (0.682, 0.756)
Seasonal vaccination After 0.64 (0.775, 0.709) 1.394 (1.055, 1.842) 0.399 (0.372, 0.428)
Never 0.43 (0.566, 0.515) 0.766 (0.586, 1.001) 0.214 (0.199, 0.230)
Gender Male 0.8 (0.769, 0.832) 0.762 (0.687, 0.846) 0.772 (0.744, 0.800)
Age 5–14 0.357 (0.333, 0.383) 0.894 (0.724, 1.103) 0.365 (0.341, 0.390)
15–44 0.189 (0.178, 0.201) 0.586 (0.483, 0.711) 0.197 (0.185, 0.209)
45–64 0.171 (0.159, 0.183) 0.312 (0.250, 0.388) 0.148 (0.139, 0.158)
65–74 0.178 (0.161, 0.197) 0.152 (0.106, 0.217) 0.133 (0.120, 0.146)
75+ 0.154 (0.138, 0.173) 0.042 (0.024, 0.076) 0.106 (0.095, 0.117)
Vaccinated in previous season Yes 1.382 (1.273, 1.502) 1.398 (1.106, 1.768) 1.319 (1.240, 1.403)
No. of ILIARI in previous season 1 2.579 (2.447, 2.719) 1.708 (1.459, 2.000) 2.219 (2.114, 2.329)
2+ 4.728 (4.438, 5.038) 2.438 (1.923, 3.091) 3.767 (3.549, 3.998)
In clinical risk group Yes 1.338 (1.249, 1.433) 1.645 (1.387, 1.950) 1.933 (1.823, 2.050)
Carstairs quintile Q2 1.065 (0.981, 1.157) 1.576 (1.273, 1.951) 1.027 (0.953, 1.106)
Q3 0.987 (0.921, 1.057) 1.321 (1.094, 1.596) 0.934 (0.877, 0.994)
Q4 0.976 (0.91, 1.046) 0.981 (0.807, 1.193) 0.983 (0.925, 1.045)
Q5 1.086 (1.011, 1.168) 1.14 (0.931, 1.395) 0.934 (0.874, 0.998)
Unknown 1.005 (0.763, 1.324) 1.565 (0.824, 2.972) 1.011 (0.785, 1.301)
Results are relative to the baseline group which is females aged 0–4 in no clinical risk group and in Carstair’s deprivation quintile 1 who did not receive a seasonal
influenza vaccination in the previous season, had no ILIARI consultations in the previous season, prior to receiving the seasonal influenza vaccination in season 2009/10
and prior to receiving the H1N1 vaccination in season 2009/10 in week 1 (1st–7th October). RRs for the specific weeks are not presented. Analysis is based upon
consultations up to 31st January 2010.ILI: Influenza-like illness, ILIARI: Influenza-like illness and acute respiratory infections (excluding asthma), ARI: All influenza-like
illness and acute respiratory infections (including asthma).
doi:10.1371/journal.pone.0028743.t005
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aged 65 and over. There is also a bias associated with deprivation
in that patients in a more deprived neighbourhood are more likely
to be swabbed, but no bias associated with risk group membership,
seasonal vaccination in the previous year and number of
consultation for ILIARI in the previous year.
A total of 508 tested positive for H1N1v influenza, yielding
positivity rate of 29.7%. The majority of these patients were
unvaccinated at the time of swabbing (1657); and only 54 were
swabbed post vaccination. Among those not vaccinated, swab
positivity is higher among those in a risk group (403 positive, 920
negative) compared to those not in a risk group (102 positive, 232
negative), p=0.002. Very few vaccinated patients were tested 254
patients and only 3 were positive for H1N1v. Trends in swab
positivity are presented in Figure 1 where it is seen that positivity
peaked in October 2009 and decreased over time among those
unvaccinated.
The results of fitting the logistic regression with a quadratic
temporal trend in week to swab positivity results are presented in
Table 8. Alternative means of controlling for the temporal trend
were considered - a spline trend within a generalised additive
Table 6. Hazard ratio of consultation estimated by Cox proportional hazards regression for the three consultation groupings.
ILIARI ILI ARI
Variable Level HR 95% CI HR 95% CI HR 95% CI
Pandemic vaccination Yes 1.128 (1.033, 1.232) 0.507 (0.323, 0.797) 1.044 (0.970, 1.123)
Gender Male 0.801 (0.770, 0.834) 0.763 (0.687, 0.846) 0.778 (0.750, 0.806)
Age 5–14 0.355 (0.331, 0.380) 0.957 (0.777, 1.179) 0.355 (0.332, 0.379)
15–44 0.188 (0.177, 0.200) 0.635 (0.524, 0.768) 0.191 (0.180, 0.202)
45–64 0.172 (0.161, 0.184) 0.339 (0.272, 0.421) 0.152 (0.142, 0.162)
65–74 0.202 (0.183, 0.223) 0.172 (0.121, 0.244) 0.201 (0.184, 0.220)
75+ 0.174 (0.156, 0.194) 0.048 (0.027, 0.086) 0.155 (0.141, 0.171)
Seasonal vaccination Yes 0.993 (0.917, 1.075) 1.523 (1.184, 1.960) 0.724 (0.678, 0.773)
Vaccinated in previous season Yes 1.778 (1.649, 1.916) 1.398 (1.136, 1.721) 2.665 (2.513, 2.826)
No. of ILIARI in previous season 1 2.612 (2.478, 2.754) 1.700 (1.452, 1.990) 2.329 (2.219, 2.444)
2+ 4.809 (4.514, 5.124) 2.411 (1.902, 3.058) 3.995 (3.764, 4.240)
In clinical risk group Yes 1.524 (1.429, 1.626) 1.565 (1.334, 1.837) 3.113 (2.957, 3.277)
Carstairs quintile Q2 1.050 (0.967, 1.141) 1.589 (1.284, 1.967) 0.963 (0.895, 1.038)
Q3 0.970 (0.905, 1.039) 1.319 (1.092, 1.593) 0.868 (0.816, 0.924)
Q4 0.970 (0.905, 1.039) 0.993 (0.816, 1.207) 0.958 (0.901, 1.019)
Q5 1.076 (1.001, 1.157) 1.153 (0.942, 1.411) 0.896 (0.839, 0.958)
Unknown 0.991 (0.752, 1.305) 1.579 (0.831, 2.999) 0.944 (0.733, 1.215)
Results are relative to the baseline group which is females aged 0–4 in no clinical risk group and in Carstairs deprivation quintile 1 who did not receive a seasonal
influenza vaccination in the previous season or the current season, had no ILIARI consultations in the previous season and did not receive the H1N1 vaccination in
season 2009/10. ILI: Influenza-like illness, ILIARI: Influenza-like illness and acute respiratory infections (excluding asthma), ARI: All influenza-like illness and acute
respiratory infections (including asthma).
doi:10.1371/journal.pone.0028743.t006
Table 7. VE estimates produced by each of the statistical methods with associated 95% confidence intervals for the three
consultation coding groupings: ILIARI, ILI and ARI.
ILIARI ILI ARI
Adjustment Method VE 95% CI VE 95% CI VE
Time only Poisson before/after 14.1 (5.4, 21.9) 19.1 (217.5, 50.6) 20.4 (13.9, 26.5)
Poisson unvaccinated/vaccinated 271.0 (284.8, 258.2) 22.3 (219.7, 49.6) 2121.8 (2136.8, 2107.9)
Cox proportional hazards 269.4 (283.1, 256.7) 23.8 (217.5, 50.6) 2120.2 (2135.0, 2106.3)
Clustered Cox proportional hazards 269.4 (298.5, 244.5) 23.8 (228.6, 54.8) 2120.2 (2152.1, 292.2)
Unadjusted Screening 34.1 (25.6, 45.5) 20.3 (13.8, 29.8) 46.5 (35.0, 61.8)
Covariate and time adjusted Poisson before/after 27.7 (218.6, 2.3) 34.2 (20.05, 58.9) 18.0 (11.2, 24.2)
Poisson unvaccinated/vaccinated 213.8 (224.2, 24.2) 48.7 (19.4,67.3) 25.1 (213.1, 2.4)
Cox proportional hazards 212.8 (223.2, 23.3) 49.3 (20.3, 67.7) 24.37 (212.3, 3.0)
Clustered Cox proportional hazards 212.8 (227.7, 0.3) 49.3 (13.6, 70.2) 24.37 (218.5, 8.1)
Analysis is based upon consultations up to 31st January 2010.
doi:10.1371/journal.pone.0028743.t007
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model for the weekly temporal trend and a factor with 4 levels
representing the 4 four week period. The parameter estimates
were relatively unaffected by the method of estimating the trend
and the estimates from the most parsimonious model using a
quadratic trend are discussed. Adjusting for the other factors in the
model there is no evidence of any effect on swab positivity of
seasonal vaccination status, risk group, deprivation and gender.
There are trends with Age group, p,0.0001, with greater swab
positivity among those aged 5–14 and 15–44 years. There was no
evidence of any interactions with vaccination status and similar
results were obtained for the vaccine effects when considering only
those in a risk group. Relative to those who were unvaccinated at
the time of swabbing the odds ratio of testing positive is 0.40 (95%
CI 0.11, 1.38), p=0.17. This corresponds to a vaccine effect of
60% (95% CI 238%, 89%).
Vaccine effectiveness – death outcome
A total of 623 patients are recorded on the GP systems as having
died in the 4 month study period giving a crude death rate of 9.8
per 1000 population per year (95% CI 9.0, 10.5) compared to the
Scottish rate of 10.5 per 1000 population per year. This suggests
under reporting of deaths on the GP systems.
The parameter estimates from the Cox regression model are
presented in Table 9. Pandemic vaccine is associated with a
reduction in the risk of death with a relative risk of 0.60, (95% CI
0.44, 0.82) and this is similar to the relative risk associated with the
use of seasonal flu vaccine 0.52 (95% CI 0.42, 0.64). Temporal
changes in the vaccine effects for the death outcome are presented
in Table 10. The H1N1v vaccine effect clearly wanes over time
and once the pandemic has ceased there is no vaccine effect on
mortality. For seasonal influenza vaccination the pattern is similar
though the effects persist during the winter season but once the
pandemic H1N1v activity has ceased.
Discussion
This study has provided vaccine effect estimates for the
pandemic influenza A H1N1v vaccine for consultations, virology
Figure 3. Graphical representation of the VE estimates
produced by month by each of the statistical models with
associated 95% confidence intervals for the ILI consultation
grouping.
doi:10.1371/journal.pone.0028743.g003
Figure 4. Graphical representation of the VE estimates
produced by month by each of the statistical models with
associated 95% confidence intervals for the ILIARI consultation
grouping.
doi:10.1371/journal.pone.0028743.g004
Figure 5. Graphical representation of the VE estimates
produced by month by each of the statistical models with
associated 95% confidence intervals for the ARI consultation
grouping.
doi:10.1371/journal.pone.0028743.g005
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and death. Comparing unvaccinated with vaccinated the vaccine
effect was 60% (95% CI 238%, 89%) for virology confirmed
influenza cases, among patients with symptoms, 49% (95% CI
19%, 67%) for ILI consultations, and 40% (95% CI 18%, 56%)
for overall mortality; the latter two among all patients in the
cohort. There was no significant vaccine effect for ILIARI and
ARI consultations with negative estimates. The virology estimate
was not significant and not inconsistent with those based upon the
test negative design, [2–5], though it is towards the lower limit of
the confidence intervals. The low number of vaccinated
individuals who are swabbed is the main reason for the
imprecision in the estimate.
In this study the results about the effect of the seasonal influenza
vaccine are conflicting. The analysis of ILI consultations showed
that patients who received the seasonal flu vaccine in the current
season had a 53% increase in consultations (95% CI 18%, 96%)
this slightly greater than the effect of receiving seasonal vaccine in
the previous year, 40% (95% CI 14%, 72%). This result is
consistent with the increased risk of medically attended ILI
reported by Skowronski et al. [14], however the virology analysis
does not confirm this as it shows a non-significant 19% increase.
The consultation rates for ILIARI and ARI are reduced among
patients who received the seasonal flu vaccine.
The vaccine effectiveness estimate varies dependent on the
group of clinical codes used within the cohort for the description of
their respiratory infection. Thus a different answer on effectiveness
is obtained dependent on whether we chose just influenza like
illness (ILI) or all acute respiratory infections (including influenza
like illness) (ARI) and whether we include or exclude asthma
exacerbations within this category (ILIARI). Although ILI
conditions alone may be more specific, the number of observations
in the PIPeR cohort are relatively small hence the VE estimate
and confidence intervals around any estimate vary widely for a
long period before a more precise estimate is obtained. For
ILIARI we have a greater number of observations and this
addresses the problem of variability in general practice recording,
whereby there may be failure to record ILI as a diagnosis,
particularly in young children or individuals with milder disease
manifestation. However, the lower specificity of the ILIARI code
grouping may lead to underestimation of the vaccine effectiveness
estimate. In the adjusted models we present, the less specific
ILIARI code grouping consistently produced the lowest VE
estimate.
Using the ARI grouping, the VE estimate obtained by all
methods is greater than the estimate obtained for ILIARI, which
differs only by excluding asthma codes. Whilst a range of
respiratory pathogens can induce exacerbations of asthma,
influenza is a potent precipitant of asthma episodes either by
itself or as a consequence of co-infection with other respiratory
viruses or by virtue of secondary bacterial infections that may
follow the initial influenza infection. This is particularly so in
younger people. The finding of a further reduction in clinical
presentations after vaccination from the Poisson regression model
comparing before vaccination with after vaccination, leading to an
Table 8. Odds ratios and 95% confidence intervals for the effects of the listed factors on H1N1v swab positivity among patients
under 65 who were swabbed as part of the Scottish Sentinel Swabbing Scheme.
GAM Quadratic Four Week Factor
Factor Level OR 95% CI P OR 95% CI P OR 95% CI P
Pandemic Vaccine No 1.00 - 1.00 - 1.00 -
Yes 0.42 (0.12, 1.46) 0.170 0.40 (0.11, 1.38) 0.145 0.39 (0.11, 1.36) 0.139
Seasonal Vaccine No 1.00 - 1.00 - 1.00 -
Yes 1.19 (0.70, 2.02) 0.520 1.19 (0.70, 2.02) 0.521 1.14 (0.67, 1.93) 0.635
Risk Group No 1.00 - 1.00 - 1.00 -
Yes 0.84 (0.62, 1.13) 0.256 0.85 (0.63, 1.14) 0.272 0.86 (0.64, 1.15) 0.305
Age Group ,1 1.00 - 1.00 - 1.00 -
1–4 2.05 (0.24, 17.65) 0.514 2.11 (0.25, 18.12) 0.496 2.12 (0.25, 18.10) 0.493
5–14 7.38 (0.87, 62.87) 0.068 7.61 (0.90, 64.58) 0.063 7.60 (0.90, 64.30) 0.063
15–44 3.72 (0.44, 31.53) 0.228 3.87 (0.46, 32.66) 0.213 3.87 (0.46, 32.52) 0.213
45–64 2.05 (0.24, 17.65) 0.512 2.13 (0.25, 18.24) 0.490 2.13 (0.25, 18.14) 0.490
65–74 0.70 (0.07, 6.97) 0.761 0.72 (0.07, 7.13) 0.778 0.74 (0.08, 7.34) 0.799
75+ 0.29 (0.02, 3.83) 0.350 0.31 (0.02, 4.07) 0.375 0.31 (0.02, 4.06) 0.374
Gender Female 1.00 - 1.00 - 1.00 -
Male 1.01 (0.80, 1.27) 0.960 1.00 (0.79, 1.26) 0.999 1.01 (0.80, 1.27) 0.945
Carstairs Quintile
(Deprivation)
Q1 1.00 - 1.00 - 1.00 -
Q2 1.30 (0.77, 2.18) 0.323 1.29 (0.77, 2.16) 0.336 1.25 (0.75, 2.09) 0.395
Q3 1.43 (0.90, 2.29) 0.132 1.42 (0.89, 2.27) 0.140 1.40 (0.88, 2.24) 0.157
Q4 1.20 (0.76, 1.92) 0.435 1.20 (0.75, 1.91) 0.445 1.20 (0.75, 1.92) 0.438
Q5 1.31 (0.83, 2.08) 0.244 1.30 (0.82, 2.06) 0.262 1.29 (0.81, 2.03) 0.281
Unknown 1.44 (0.43, 4.87) 0.557 1.46 (0.44, 4.90) 0.540 1.48 (0.44, 4.94) 0.527
The swabs were all collected between October 1st 2009 and 31st January 2010. Three different models were used to control for the temporal trend – a spline trend
within a generalised additive model (GAM) for the weekly temporal trend; a quadratic trend; and a factor with 4 levels representing the 4 four week period.
doi:10.1371/journal.pone.0028743.t008
Variation in Influenza Vaccine Effectiveness
PLoS ONE | www.plosone.org 10 December 2011 | Volume 6 | Issue 12 | e28743
increased VE estimate when all acute respiratory infections
including asthma are measured, is then an expected finding.
There are, however interpretational difficulties associated with
differentiating between consultations associated with environmen-
tal challenges rather than infective challenges in asthma
exacerbations. Therefore the estimate of VE may be inflated
artificially by inclusion of asthma codes. It should also be noted
that, the specificity of the ARI and ILIARI categories will be
influenced by the incidence of influenza relative to other
circulating respiratory illness and therefore using ILI consultations
for estimations is the preferred choice. In non-pandemic years,
there has however been a lack of recording of the class despite
influenza circulating. It is therefore essential that other groupings
are available for analysis.
The vaccine effectiveness estimate was also found to depend on
the statistical methodology used. For ILI the estimates were similar
Table 9. Hazard ratios of death, with 95% confidence limits, estimated by Cox proportional hazards regression.
Factor Level HR 95% CI P-value
Pandemic Vaccine No 1.00 -
Yes 0.60 (0.44, 0.82) 0.001
Seasonal Vaccine No 1.00 -
Yes 0.52 (0.42, 0.64) 0.000
Seasonal Vaccine No 1.00 -
Previous Season Yes 1.45 (1.18, 1.78) 0.000
Number of ILIARI consultations in previous year 0 1.00 -
1 1.19 (0.89, 1.58) 0.251
2 1.12 (0.60, 2.09) 0.732
3+ 2.74 (1.61, 4.66) 0.000
Risk Group No 1.00 -
Yes 4.96 (3.99, 6.17) 0.000
Age Group ,14 1.00 -
15–44 2.44 (0.73, 8.18) 0.149
45–64 11.39 (3.59, 36.13) 0.000
65–74 77.75 (24.51, 246.62) 0.000
75+ 355.21 (112.98, 1116.77) 0.000
Gender Female 1.00 -
Male 1.25 (1.06, 1.46) 0.007
Carstairs Quintile (Deprivation) Q1 1.00 -
Q2 0.99 (0.70, 1.40) 0.945
Q3 0.85 (0.63, 1.15) 0.290
Q4 1.01 (0.75, 1.36) 0.964
Q5 1.10 (0.81, 1.51) 0.536
Unknown 1.30 (0.47, 3.60) 0.611
doi:10.1371/journal.pone.0028743.t009
Table 10. Vaccine effect on overall mortality estimated by Poisson regression in various time periods after the beginning of the
study.
Start End Epidemic period Pandemic H1N1v Vaccine Seasonal Vaccine
VE 95% CI P-value VE 95% CI P-value
01/10/2009 25/11/2009 Peak 100.0 - - 71.6 (57.0, 81.3) 0.000
26/11/2009 23/12/2009 Wane 62.4 (24.6, 81.2) 0.006 49.1 (23.2, 66.3) 0.001
24/12/2009 20/01/2010 Wane 38.3 (8.2, 58.5) 0.017 18.7 (222.4, 46.0) 0.321
21/01/2010 17/02/2010 After 30.8 (23.3, 53.6) 0.072 52.2 (27.0, 68.6) 0.001
18/02/2010 17/03/2010 After 20.9 (248.3, 31.3) 0.963 24.5 (220.7, 52.8) 0.240
18/03/2010 30/04/2010 After 1.7 (236.1, 29.0) 0.918 215.7 (275.6, 23.8) 0.495
In the first period from 1/10/2009 to 25/11/2009 no pandemic H1N1v vaccinated individuals died hence the VE is estimated as 100% and no confidence intervals
supplied.
doi:10.1371/journal.pone.0028743.t010
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however adjustment for confounding variables and propensity to
consult had a larger effect for the two methods based upon the
comparison of vaccinated with unvaccinated. This is because the
vaccine effect is essentially a between person estimate in these
models whereas in the before vaccination after vaccination
framework there is a matching with the same individuals in both
groups. The before vaccination after vaccination framework
method should produce more precise results by directly accounting
for possible differences in the propensity to consult between the
vaccinated and unvaccinated individuals though will not do so if
the propensity changes post vaccination. Furthermore, the before
after framework is retrospective, in that it is vaccine status at the
end of the season which determines the exposure group and this is
not as statistically valid as the prospective framework for the time
dependent Cox model or Poisson Regression model.
For both ILIARI and ARI there is a large change in the vaccine
effect estimates associated with adjustment for confounding from
the two methods comparing vaccinated and unvaccinated patients.
For all three methods the adjustment serves to increase the
estimated vaccine effect.
The more simplistic screening method, based on aggregate data
and unadjusted for time and covariates, gave similar results to the
other methods for ILI but for the less specific consultation
groupings gave over estimates of the effectiveness. This is likely
due to the lack of adjustment the healthy vaccine effect and the
change in consultation patterns across the time frame considered.
Linking the cohort to all virology tests in Scotland has shown
some of the biases in having a swab and it was demonstrated that
patients aged 15–44 who had symptoms were more likely to be
swabbed that older and younger symptomatic patients. It was
demonstrated that having a swab was unrelated to gender,
membership of a risk group, having had the seasonal vaccination
in the previous year and number of consultations in the previous
year. Other than age the only other determinant of swabbing was
deprivation and this is may be associated with swabbing frequency
in the general practices.
Using death as an endpoint yields results which are difficult to
interpret as both the pandemic vaccine and the seasonal vaccine
are independently associated with a reduction in the risk of death.
During the 2009–10 pandemic season the confirmed death rate
from Influenza A H1N1v was low and a 40% reduction in death
rate from influenza vaccine is rather large – however this is a
relative reduction in mortality. We cannot discount, however, that
the effect is not a ‘healthy vaccinate effect’ in that frail patients
were not less likely to be vaccinated and this would certainly
explain both the pandemic and seasonal vaccine effects. The
trends over time in this effect show that the effects are present
during the winter period when there are traditionally higher death
rates, particularly among those over 65.
Overall, this analysis has provides support for an association
between influenza and increased consultations. The low levels of
VE may be related in part to the fact that Influenza A H1N1v
activity had begun to wane by the time vaccine was distributed.
Similar estimates of vaccine effect have been found using different
methodologies but the results are found to vary with the measure
of outcome used. Understanding the variation in the estimates
between the methods used and the outcome considered aids
analysis and interpretation of vaccine effectiveness results in future
seasons.
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